GLSI - Greenwich LifeSciences Inc Ordinary Shares (Healthcare: Biotechnology) Projected Earnings Date: 2024-08-26    (Delayed quote data   2025-05-09)
Last
 9.43		 Change
 ⇓ -0.23   (-2.38%)		 Volume
  13,699
Open
 9.67		 High
 9.76		 Low
 9.33
8EMA (Daily)
 9.71		 40EMA (Daily)
 10.16		 50EMA (Daily)
 10.37		 STO (Daily)
 46.757		 MACD Hist (Daily)
 0.023
8EMA (Weekly)
 10.035		 40EMA (Weekly)
 12.02		 50EMA (Weekly)
 12.24		 STO (Weekly)
 25.768		 MACD Hist (Weekly)
 -0.331
Company Profile
Greenwich LifeSciences Inc is a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in most breast cancers at low, intermediate, and high or overexpressor levels.
optionchance optionchance
⇒ Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com